[1] Cohen-Naftaly M,Friedman SL.Current status of novel antifibrotic therapies in patients with chronic liver disease[J].Therap Adv Gastroenterol,2011,4:391-417. [2] Puche JE,Saiman Y,Friedman SL.Hepatic stellate cells and liver fibrosis[J].Compr Physiol,2013,3:1473-1492. [3] Hernandez-Gea V,Friedman SL.Pathogenesis of liver fibrosis[J].Annu Rev Pathol,2011,6:425-456. [5] 秦棪楠,钟耀刚,李铮.人肝星状细胞激活和抑制及其相关分子机制的研究进展[J].中国细胞生物学报,2011,33(10):1127-1136. [6] 徐向南,肖永胜,樊嘉.肝星状细胞与肝癌的研究进展[J].中国临床医学,2012,19(6):705-707. [7] 孙华丽,张建军.组织金属蛋白酶及其抑制因子与肝纤维化[J].西南军医,2010,12(1):81-82. [8] Chen YL,Li ZY.The relationship between TGF-β1,PDGF-BB,CTGF and chronic hepatitis B with fibrosis[J].Chin J Diffic Compl Cas,2010,9(1):19-20. [9] 李媛,宋媛媛,张洪泉.肉苁蓉的化学成分及药理作用研究进展[J].中国野生植物资源,2010,29(1):7-12. [10] 宋鹏,屠鹏飞.中药肉苁蓉质量控制及评价的研究进展[J].北方药学,2011,8(2):61-62. [11] 屠鹏飞,姜勇,郭玉海.肉苁蓉研究及其产业发展[J].中国药学杂志,2011,46(12):882-888. [12] 陈海燕,郝彩琴,郭鸿雁.肉苁蓉药用资源开发与应用研究进展[J].价值工程,2012,31(3):303-305. [13] 赵微,潘英妮.肉苁蓉苯乙醇苷类成分药理作用研究进展[J].亚太传统医药,2013,9(5):77-79. [14] 孙朝晖.中药肉苁蓉的药理活性研究进展[J].赤峰学院学报:自然科学版,2010,26(2):70-71. [15] 木克热木·吐地买提,由淑萍,赵军,等.肉苁蓉苯乙醇苷类成分对BSA致大鼠肝纤维化影响的实验研究[J].新疆医科大学学报,2015,38(5):567-570. [16] Xu R,Zhang Z,Wang FS.Liver fibrosis:mechanisms of immune-mediated liver injury[J].Cell Mol Immunol,2012,9(4):296-301. [17] Bahadar H,Maqbool F,Niaz K,et al.Toxicity of nanoparticles and an overview of current experimental models[J].Iran Biomed J,2016,20(1):1-11. [18] Shu-Ping You,Jun Zhao,Long Ma,et al.Preventive effects of phenylethanol glycosides from Cistanchetubulosa on bovine serum albumin induced hepatic fibrosis in rats[J].Daru,2015,23:52.doi:10.1186/s40199-015-0135-4. [19] Zhao XK,Cheng ML,Wu RM,et al.Effect of Danshao Huaxian capsule on GremLin and bone morphogenetic protein-7 expression in hepatic fibrosis in rats[J].World J Gastroenterol,2014,20(40):14875-14883. |